Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA.

The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug.

The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

An enhanced protocol will be detemined with both Australian and U.K. regulators and hospital sites, with patients expected to be enrolled in the second half of 2016.

Importantly, a U.S. focused study and protocol design will allow for broader value creation, as the U.S. is the largest market for Alzheimer’s drugs.

Xanamem has been specifically designed to inhibit the excess production of cortisol, the ‘stress hormone’ in the brain.

Recent global research has demonstrated that excess cortisol is associated with cognitive decline and neurotoxicity in the brain, which are the hallmarks of Alzheimer’s disease.

In 2015 the total estimated global cost of treating Alzheimer’s was close to US$1 trillion.

The potential upside for a successful drug is significant, which has helped Actinogen share price almost double during the last six months.

The phase II study is fully funded through to completion with $6.8 million cash as on 31 March 2016.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

t-cell
Wed
£1,000 invested at float two years ago would now be worth just north of £3,500
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use